Publication: Diseño, desarrollo y evaluación de formulaciones de administración vaginal para la prevención de la transmisión sexual del VIH
Loading...
Official URL
Full text at PDC
Publication Date
2021-04-21
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
La infección por el virus de inmunodeficiencia humana (VIH) es un problema de salud pública a nivel mundial, pero su incidencia es particularmente preocupante entre las mujeres jóvenes de países de bajos y medios ingresos. Diversos factores predisponen a este grupo poblacional a estar más expuesto al contagio, tales como la violencia sexual, la pobreza y la falta de poder de decisión sobre su propia salud sexual. Son estas circunstancias las que han llevado al estudio de los microbicidas vaginales como una herramienta para prevenir la transmisión sexual del virus. Los primeros microbicidas fueron diseñados para una administración diaria, pero la falta de frecuencia en su uso observada en ensayos clínicos llevó a la búsqueda de formas farmacéuticas que permitieran una posología más cómoda. En la actualidad, la investigación en el campo de los microbicidas vaginales sigue siendo particularmente intensa, explorándose el uso de formas farmacéuticas alternativas, la cada vez más presente aplicación de nanosistemas para la liberación de fármacos, o incluso el uso de probióticos modificados genéticamente para la expresión de sustancias con potencial viricida. A pesar de ello, el desarrollo de microbicidas vaginales aún tiene un largo camino por recorrer, como demuestra el hecho de que todavía no exista ningún producto comercializado para este fin...
The infection by human immunodeficiency virus (HIV) is a global public health problem, but its incidence is particularly worrisome in women from low- and middle-income countries. Several factors predispose this population group to be more exposed to sexual acquisition of the virus, such as the frequency of sexual violence, poverty and the lack of decision-making power over their own sexual health. These circumstances have led to the study of vaginal microbicides as a tool to prevent the sexual transmission of the virus.The first microbicides developed were designed for daily administration, but the low frequency of use led to the search for pharmaceutical forms that allow a most convenient dosage. Currently, research in the field of vaginal microbicides continues to be particularly intense, looking into alternative pharmaceutical forms, the application of nanosystems for drug delivery, or even the use of genetically modified probiotics for the release of viricidal substances. Despite this, the development of vaginal microbicides still has a long way to go, as evidenced by the fact that there are still no commercialised products for this purpose...
The infection by human immunodeficiency virus (HIV) is a global public health problem, but its incidence is particularly worrisome in women from low- and middle-income countries. Several factors predispose this population group to be more exposed to sexual acquisition of the virus, such as the frequency of sexual violence, poverty and the lack of decision-making power over their own sexual health. These circumstances have led to the study of vaginal microbicides as a tool to prevent the sexual transmission of the virus.The first microbicides developed were designed for daily administration, but the low frequency of use led to the search for pharmaceutical forms that allow a most convenient dosage. Currently, research in the field of vaginal microbicides continues to be particularly intense, looking into alternative pharmaceutical forms, the application of nanosystems for drug delivery, or even the use of genetically modified probiotics for the release of viricidal substances. Despite this, the development of vaginal microbicides still has a long way to go, as evidenced by the fact that there are still no commercialised products for this purpose...
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Farmacia, leída el 01-12-2020